Literature DB >> 19123864

Use of T cell-based diagnosis of tuberculosis infection to optimize interpretation of tuberculin skin testing for child tuberculosis contacts.

Mustafa Bakir1, Davinder P S Dosanjh, Jonathan J Deeks, Ahmet Soysal, Kerry A Millington, Serpil Efe, Yasemin Aslan, Dilek Polat, Nihat Kodalli, Aysegul Yagci, Isil Barlan, Nerin Bahceciler, Emel E Demiralp, Ajit Lalvani.   

Abstract

BACKGROUND: Treatment of recent tuberculosis infection in children aged <2 years is essential, because of high risk of progression to disease, but diagnosis is hindered by the inaccuracy of the tuberculin skin test (TST). More-accurate T cell-based tests of infection could enhance diagnosis by optimizing interpretation of the TST results.
METHODS: A total of 979 child tuberculosis contacts in Istanbul underwent the TST and enzyme-linked immunospot assay. Using enzyme-linked immunospot test results as a reference standard, we assessed the effect of age and bacille Calmette-Guérin (BCG) vaccination on the sensitivity and specificity of the TST, and we computed the optimal TST cutoff points, using receiver operating characteristic curves.
RESULTS: With a TST cutoff point of >or=10 mm, the sensitivity of the TST was 66% for children aged <2 years, which was lower than that for older children (P= .006). Specificity was 75% for BCG-vaccinated children, compared with 92% for unvaccinated children (P= .001). Optimal cutoff points improved TST specificity for children with 1 BCG scar, with little loss of sensitivity. Despite the use of optimal cutoff points, TST sensitivity remained <70% for children aged <2 years, specificity remained <87% for BCG-vaccinated children aged >or=2 years, and overall accuracy was low for children with >1 BCG scar.
CONCLUSIONS: Negative results of the TST cannot exclude tuberculosis infection for child tuberculosis contacts aged <2 years, which supports the use of preventive therapy regardless of the TST results for this age group. In children aged >or=2 years, the accuracy of the TST can be improved by adjustment of cutoff points for BCG-vaccinated children but remains poor for children with >1 BCG scar. This methodology can define optimal TST cutoff points for diagnosis of tuberculosis infection tailored to target populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19123864      PMCID: PMC2854802          DOI: 10.1086/595847

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

Review 1.  Childhood tuberculosis during the 1990s.

Authors:  J R Starke
Journal:  Pediatr Rev       Date:  1992-09

2.  Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice.

Authors:  T Meier; H-P Eulenbruch; P Wrighton-Smith; G Enders; T Regnath
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 3.  An update on the diagnosis of tuberculosis infection.

Authors:  Luca Richeldi
Journal:  Am J Respir Crit Care Med       Date:  2006-06-23       Impact factor: 21.405

4.  Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis.

Authors:  Philip C Hill; Roger H Brookes; Ifedayo M O Adetifa; Annette Fox; Dolly Jackson-Sillah; Moses D Lugos; Simon A Donkor; Roger J Marshall; Stephen R C Howie; Tumani Corrah; David J Jeffries; Richard A Adegbola; Keith P W J McAdam
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

Review 5.  T cell-based diagnosis of childhood tuberculosis infection.

Authors:  Ajit Lalvani; Kerry A Millington
Journal:  Curr Opin Infect Dis       Date:  2007-06       Impact factor: 4.915

6.  T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure.

Authors:  Luca Richeldi; Katie Ewer; Monica Losi; Barbara M Bergamini; Pietro Roversi; Jonathan Deeks; Leonardo M Fabbri; Ajit Lalvani
Journal:  Am J Respir Crit Care Med       Date:  2004-05-06       Impact factor: 21.405

7.  Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells.

Authors:  Ann L N Chapman; Mwansa Munkanta; Katalin A Wilkinson; Ansar A Pathan; Katie Ewer; Helen Ayles; William H Reece; Alwyn Mwinga; Peter Godfrey-Faussett; Ajit Lalvani
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

8.  Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis.

Authors:  A K Detjen; T Keil; S Roll; B Hauer; H Mauch; U Wahn; K Magdorf
Journal:  Clin Infect Dis       Date:  2007-06-15       Impact factor: 9.079

9.  Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents.

Authors:  K H Hsu
Journal:  JAMA       Date:  1984-03-09       Impact factor: 56.272

10.  The tuberculin sensitivity in BCG vaccinated infants and children in Israel.

Authors:  J H Marcus; Y Khassis
Journal:  Acta Tuberc Pneumol Scand       Date:  1965
View more
  11 in total

1.  Kinetics of a tuberculosis-specific gamma interferon release assay in military personnel with a positive tuberculin skin test.

Authors:  Sigrid E van Brummelen; Anja M Bauwens; Noël J Schlösser; Sandra M Arend
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

Review 2.  Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.

Authors:  Victoria O Kasprowicz; Gavin Churchyard; Stephen D Lawn; S Bertel Squire; Ajit Lalvani
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

3.  Tuberculin skin test in bacille Calmette-Guérin-vaccinated children: how should we interpret the results?

Authors:  Roi Piñeiro; María José Mellado; María José Cilleruelo; Marta García-Ascaso; Antonio Medina-Claros; Milagros García-Hortelano
Journal:  Eur J Pediatr       Date:  2012-07-01       Impact factor: 3.183

4.  Does BCG vaccination protect against infection with M. tuberculosis?

Authors:  P T Pelzer; Y Smit; E W Tiemersma; N T Huong; N V Nhung; F Cobelens
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

5.  Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity.

Authors:  Peter J Dodd; Kerry A Millington; Azra C Ghani; Junior Mutsvangwa; Anthony E Butterworth; Ajit Lalvani; Elizabeth L Corbett
Journal:  Am J Epidemiol       Date:  2010-04-09       Impact factor: 4.897

6.  Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis.

Authors:  Manish Pareek; John P Watson; L Peter Ormerod; Onn Min Kon; Gerrit Woltmann; Peter J White; Ibrahim Abubakar; Ajit Lalvani
Journal:  Lancet Infect Dis       Date:  2011-04-20       Impact factor: 25.071

7.  Novel M tuberculosis antigen-specific T-cells are early markers of infection and disease progression.

Authors:  Davinder P S Dosanjh; Mustafa Bakir; Kerry A Millington; Ahmet Soysal; Yasemin Aslan; Serpil Efee; Jonathan J Deeks; Ajit Lalvani
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

8.  Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study.

Authors:  Maunank Shah; Tafadzwa S Kasambira; Peter V Adrian; Shabir A Madhi; Neil A Martinson; Susan E Dorman
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

9.  Increased risk of Mycobacterium tuberculosis infection in household child contacts exposed to passive tobacco smoke.

Authors:  Saranya Sridhar; Nisha Karnani; David W Connell; Kerry A Millington; Davinder Dosanjh; Mustafa Bakir; Ahmet Soysal; Jonathan Deeks; Ajit Lalvani
Journal:  Pediatr Infect Dis J       Date:  2014-12       Impact factor: 2.129

10.  Determining the Latent Tuberculosis Infection by IFN - γ Elispot Assay in Healthcare Workers From University Hospitals of Shiraz, South West of Iran.

Authors:  Mohammad Taheri; Hamid Bazrafkan; Mojtaba Habibagahi
Journal:  Iran Red Crescent Med J       Date:  2013-06-05       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.